Transgene Biotek Ltd (TRABI) is currently trading at 2.55 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Transgene Biotek Ltd, founded in 1990, is a pioneering biotechnology company in India, focusing on research and development of vaccines, oncology products, and new drug delivery technologies. The company has a robust product export portfolio, reaching markets in Africa, Russia, China, Malaysia, and the Philippines. A significant development includes the planned setup of a manufacturing facility at Anrich Industrial Area with a Rs. 30 crore investment, supported by preferential offer funding from Batterymarch Financial Management USA and other financial institutions. Transgene is advancing in novel delivery systems for proteins, peptides, and biologicals, with a particular emphasis on oral and nasal formulations. The company targets novel therapies in oncology and auto-immune diseases, addressing vital areas of unmet medical need.

Over the past 52 weeks, Transgene Biotek Ltd has traded between a low of ₹2.49 and a high of ₹5.26. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Transgene Biotek Ltd has a market capitalization of approximately 20.99. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Transgene Biotek Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of N/A and operates in the Healthcare sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

You can buy shares of Transgene Biotek Ltd (TRABI) through any SEBI-registered stockbroker in India. A demat and trading account are required to place buy or sell orders on stock exchanges such as NSE or BSE. Shares are credited to the demat account as per the exchange settlement cycle.

Based on its market capitalization of 20.99 Cr, Transgene Biotek Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Transgene Biotek Ltd operates in the Healthcare sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Transgene Biotek Ltd is N/A. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Transgene Biotek Ltd currently does not pay dividends. Companies that do not pay dividends often reinvest profits to support business growth or strengthen operations.

Key risks associated with Transgene Biotek Ltd include sector-specific challenges in the Healthcare industry, regulatory changes, competitive pressures, company-level financial performance, overall market volatility, and broader macroeconomic factors that can impact stock prices.